Martinus Løvik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Martinus Løvik has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Livar Frøyland
National Institute of Nutrition and Seafood Research (NIFES), P.O.Box 2029 Nordnes, 5817, Bergen, Norway
7 shared publications - Margaretha Haugen
Department of Exposure and Risk Assessment, Norwegian Institute of Public Health, Oslo, Norway
7 shared publications - Tor Arne Strand
University of Bergen
7 shared publications Kristin Holvik
6 shared publicationsInger Therese L. Lillegaard
5 shared publications- Sigrun Henjum
Department of Nursing and Health Promotion, Faculty of Health Sciences, Oslo Metropolitan University
5 shared publications
Latest Publications
- 29 October 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 330-332
Risk Assessment of "Other Substances" – L-alanine
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the risk of "other substances" in food supplements and energy drinks sold in Norway. VKM has assessed the risk of doses given by NFSA. These risk assessments will provide NFSA with the scientific basis while regulating "other substances" in food supplements. "Other substances" are described in the food supplement directive 2002/46/EC as substances other than vitamins or minerals that have a nutritional and/ or physiological e ffect . It is added mainly to food supplements, but also to energy drinks and other foods. In this series of risk assessments of "other substances" the VKM has not evaluated any claimed beneficial effects from these substances, only possible adverse effects. For the current report VKM has studied previous risk assessments and performed two systematic literature searches for any published studies assessing negative health effects of L-alanine in humans or animals. According to information from NFSA, L-alanine is an ingredient in food supplements sold in Norway. NSFA has requested a risk assessment of L-alanine: 3500, 3750, 4000, 4250 and 4500 mg/day. Foods rich in alanine are generally protein rich foods such as meat, dairy products, legumes, fish, nuts, seeds, eggs and whole grains. Based on NHANES III (19881994), the overall mean intake of L-alanine from food and food supplements in the United States was 3.6 g/day. L-alanine is a naturally occurring non-essential α-amino acid belonging to the group of the 20 amino acids that are normal components of food proteins. L-alanine acts as an intermediary between protein catabolism and carbohydrate synthesis. It can be easily synthesised from the alpha keto acid pyruvate and has close links to several metabolic pathways including glycolysis, gluconeogenesis, and the citric acid cycle. Together with lactate it is capable of generating glucose from muscle protein through gluconeogenesis in the liver. Alanine thus plays a central role in the metabolism of muscle protein and is a key factor in nitrogen metabolism. Previous reports from the US Institute of Medicine (IOM) 2005, the French Food Safety Agency (AFSSA) 2007 and the Spanish Agency for Food Safety and Nutrition (AESAN) 2012 did not conclude regarding safe doses of L-alanine, but stated that data on adverse effects of L-alanine intake from supplements were not sufficient for a dose-response assessment and establishment of a tolerable upper intake level. Few studies have assessed health effects of L-alanine supplementation in humans, and these were generally not designed to evaluate potential harmful effects of L-alanine. Most human experimental studies gave single doses (up to 50 g) or short-term loading doses (e.g. 25 to 45 g/hour during exercise) to study metabolic responses such as ergogenic effects during exercise or prevention of ketosis after fasting. Adverse health effects were not reported except for abdominal discomfort and stomach cramps, nausea and diarrhea after consuming high doses. No studies assessed long-term effects of L-alanine supplementation, and no studies gave doses comparable to the doses under consideration in the present report. Only one dose-reponse toxicity study in rodents has been found (Chow et al., 1976). In that study, growing Wistar rats were fed up to 20% DL-alanine (a racemic mixture of D- and Lalanine) in their basal diet for 26 weeks, with no effect on liver and kidney weight and no pathological changes in any organs. The study was taken into account due to the otherwise scarce literature on L-alanine toxicity, and could be used since there were no adverse effects at the highest dose tested. The no observed adverse effect level (NOAEL) in mg L-alanine per kg body weight per day was not stated. VKM has therefore estimated the NOAEL using information about average reported feed consumption and average body weights of the animals, and divided by 2 to obtain a NOAEL for L-alanine, arriving at approximately 6450 mg/kg bw/day in male rats and 9700 mg/kg bw/day in female rats. A standard toxicological approach dividing by an uncertainty factor (UF) of 10 for between-species variation and an additional UF of 10 for within-species variation gives the value of 64.5 mg/kg bw per day in females and 97.0 mg/kg bw per day in males, corresponding to approximately 4500 mg/day and 6800 mg/day for a 70 kg man and woman, respectively. VKM also calculated the margins of exposure (MOE) between the estimated NOAEL and the estimated daily exposures from the five supplement doses given by the NFSA (based on default average body weights for the age groups). MOE were 100 or higher for all five doses in adults. For adolescents 14 to <18 years, the MOE was 88 for the highest dose under consideration. For children 10 to <14 years, MOE ranged from 62 for the highest dose to 80 for the lowest dose. The VKM considers that these margins are relatively high and are acceptable based on the following considerations: The highest dose tested in growing rats did not cause adverse effects, implying that the “true” NOAEL is unknown and could be considerably higher. Furthermore, L-alanine is a nutrient participating in normal energy metabolism as a substrate for glucose. It is consumed in the magnitude of 3 to 4 g/day on average in the habitual diet, and it has not been associated with harmful effects in humans beyond gastrointestinal effects when consuming very high single doses (50 g, or at a consumption rate of 30 to 45 grams per hour during exercise). VKM concludes that: In adults (≥18 years), the specified doses 3500, 3750, 4000, 4250 and 4500 mg/day L-alanine in food supplements are unlikely to cause adverse health effects. In adolescents (14 to <18 years), the specified doses 3500, 3750, 4000, 4250 and 4500 mg/day L-alanine in food supplements are unlikely to...
- 29 October 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 330-332
Risk Assessment of "Other Substances" – L-alanine
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the risk of "other substances" in food supplements and energy drinks sold in Norway. VKM has assessed the risk of doses given by NFSA. These risk assessments will provide NFSA with the scientific basis while regulating "other substances" in food supplements. "Other substances" are described in the food supplement directive 2002/46/EC as substances other than vitamins or minerals that have a nutritional and/ or physiological e ffect . It is added mainly to food supplements, but also to energy drinks and other foods. In this series of risk assessments of "other substances" the VKM has not evaluated any claimed beneficial effects from these substances, only possible adverse effects. For the current report VKM has studied previous risk assessments and performed two systematic literature searches for any published studies assessing negative health effects of L-alanine in humans or animals. According to information from NFSA, L-alanine is an ingredient in food supplements sold in Norway. NSFA has requested a risk assessment of L-alanine: 3500, 3750, 4000, 4250 and 4500 mg/day. Foods rich in alanine are generally protein rich foods such as meat, dairy products, legumes, fish, nuts, seeds, eggs and whole grains. Based on NHANES III (19881994), the overall mean intake of L-alanine from food and food supplements in the United States was 3.6 g/day. L-alanine is a naturally occurring non-essential α-amino acid belonging to the group of the 20 amino acids that are normal components of food proteins. L-alanine acts as an intermediary between protein catabolism and carbohydrate synthesis. It can be easily synthesised from the alpha keto acid pyruvate and has close links to several metabolic pathways including glycolysis, gluconeogenesis, and the citric acid cycle. Together with lactate it is capable of generating glucose from muscle protein through gluconeogenesis in the liver. Alanine thus plays a central role in the metabolism of muscle protein and is a key factor in nitrogen metabolism. Previous reports from the US Institute of Medicine (IOM) 2005, the French Food Safety Agency (AFSSA) 2007 and the Spanish Agency for Food Safety and Nutrition (AESAN) 2012 did not conclude regarding safe doses of L-alanine, but stated that data on adverse effects of L-alanine intake from supplements were not sufficient for a dose-response assessment and establishment of a tolerable upper intake level. Few studies have assessed health effects of L-alanine supplementation in humans, and these were generally not designed to evaluate potential harmful effects of L-alanine. Most human experimental studies gave single doses (up to 50 g) or short-term loading doses (e.g. 25 to 45 g/hour during exercise) to study metabolic responses such as ergogenic effects during exercise or prevention of ketosis after fasting. Adverse health effects were not reported except for abdominal discomfort and stomach cramps, nausea and diarrhea after consuming high doses. No studies assessed long-term effects of L-alanine supplementation, and no studies gave doses comparable to the doses under consideration in the present report. Only one dose-reponse toxicity study in rodents has been found (Chow et al., 1976). In that study, growing Wistar rats were fed up to 20% DL-alanine (a racemic mixture of D- and Lalanine) in their basal diet for 26 weeks, with no effect on liver and kidney weight and no pathological changes in any organs. The study was taken into account due to the otherwise scarce literature on L-alanine toxicity, and could be used since there were no adverse effects at the highest dose tested. The no observed adverse effect level (NOAEL) in mg L-alanine per kg body weight per day was not stated. VKM has therefore estimated the NOAEL using information about average reported feed consumption and average body weights of the animals, and divided by 2 to obtain a NOAEL for L-alanine, arriving at approximately 6450 mg/kg bw/day in male rats and 9700 mg/kg bw/day in female rats. A standard toxicological approach dividing by an uncertainty factor (UF) of 10 for between-species variation and an additional UF of 10 for within-species variation gives the value of 64.5 mg/kg bw per day in females and 97.0 mg/kg bw per day in males, corresponding to approximately 4500 mg/day and 6800 mg/day for a 70 kg man and woman, respectively. VKM also calculated the margins of exposure (MOE) between the estimated NOAEL and the estimated daily exposures from the five supplement doses given by the NFSA (based on default average body weights for the age groups). MOE were 100 or higher for all five doses in adults. For adolescents 14 to <18 years, the MOE was 88 for the highest dose under consideration. For children 10 to <14 years, MOE ranged from 62 for the highest dose to 80 for the lowest dose. The VKM considers that these margins are relatively high and are acceptable based on the following considerations: The highest dose tested in growing rats did not cause adverse effects, implying that the “true” NOAEL is unknown and could be considerably higher. Furthermore, L-alanine is a nutrient participating in normal energy metabolism as a substrate for glucose. It is consumed in the magnitude of 3 to 4 g/day on average in the habitual diet, and it has not been associated with harmful effects in humans beyond gastrointestinal effects when consuming very high single doses (50 g, or at a consumption rate of 30 to 45 grams per hour during exercise). VKM concludes that: In adults (≥18 years), the specified doses 3500, 3750, 4000, 4250 and 4500 mg/day L-alanine in food supplements are unlikely to cause adverse health effects. In adolescents (14 to <18 years), the specified doses 3500, 3750, 4000, 4250 and 4500 mg/day L-alanine in food supplements are unlikely to...
- 29 October 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 336-338
Risk Assessment of "Other Substances"-Beta-Alanine
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the risk of "other substances" in food supplements and energy drinks sold in Norway. VKM has assessed the risk of doses given by NFSA. These risk assessments will provide NFSA with the scientific basis while regulating "other substances" in food supplements. "Other substances" are described in the food supplement directive 2002/46/EC as substances other than vitamins or minerals that have a nutritional and/or physiological effect. It is added mainly to food supplements, but also to energy drinks and other foods. In this series of risk assessments of "other substances" the VKM has not evaluated any claimed beneficial effects from these substances, only possible adverse effects. The present report is a risk assessment of specified doses of beta-alanine in food supplements, and it is based on previous risk assessments and articles retrieved from literature searches. According to information from NFSA, beta-alanine is an ingredient in food supplements sold in Norway. NSFA has requested a risk assessment of beta-alanine: 1000, 1500 and 2000 mg/day from food supplements. Beta-alanine is a non-essential, non-proteogenic naturally occurring beta amino acid. Beta-alanine is a component of the naturally occurring peptides carnosine, anserine and balenine. Supplementation with beta-alanine leads to an increased production of the peptide carnosine, which is found in high concentrations in the skeletal muscle of both vertebrates and non-vertebrates. Data suggest that beta-alanine functions as a small molecule neurotransmitter and should join the ranks of the other amino acid neurotransmitters. The only observed adverse effect from beta-alanin supplementation in humans is transient (1-2 hours) paraesthesia and flushing. Paraesthesia is characterised by a stinging or prickling sensation in the skin. There is no evidence that the paraesthesia in the skin is harmful in any way. Long-term studies in humans were not found. Four small human clinical studies have been included in this risk assessment. The occurrence of paraesthesia apparently is dependent on the magnitude of the individual doses that the daily dose is split into. Single doses of beta-alanine of 10 mg/kg bw (700 mg in a 70 kg person) or more provoked transient paraesthesia. Symptom occurrence and severity increased with the dose. Repeated intakes of 5 mg beta-alanine/kg bw or less taken with >2 hours intervals did not induce paraesthesia. Haematology and plasma clinical chemistry was found normal after daily doses of 2.8 g and 3.2 g for 4 weeks in healthy adults. Apart from occasional paraesthesia, a daily dose of 6.4 g for up to seven weeks did not induce any adverse clinical effects in healthy adults of 80 kg, corresponding to a dose of 5.6 g per day in a 70-kg person. We are not aware of any data indicating that children and adolescents are more vulnerable than adults for supplementation with beta-alanine on a per kg bw basis. No relevant animal studies were identified. VKM concludes that: In adults (≥18 years), the specified doses 1000, 1500 and 2000 mg/day of beta-alanine in food supplements are unlikely to cause adverse health effects provided that beta-alanine is consumed with maximum 5 mg/kg bw per intake and a minimum of 2 hours between the intakes. In adolescents (14 to <18 years) and children (10 to <14 years) the specified doses 1000, 1500 and 2000 mg/day of beta-alanine in food supplements are unlikely to cause adverse health effects provided that beta-alanine is consumed with maximum 5 mg/kg bw per intake and a minimum of 2 hours between the intakes. Children younger than 10 years were not within the scope of the present risk assessment.
- 29 October 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 336-338
Risk Assessment of "Other Substances"-Beta-Alanine
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the risk of "other substances" in food supplements and energy drinks sold in Norway. VKM has assessed the risk of doses given by NFSA. These risk assessments will provide NFSA with the scientific basis while regulating "other substances" in food supplements. "Other substances" are described in the food supplement directive 2002/46/EC as substances other than vitamins or minerals that have a nutritional and/or physiological effect. It is added mainly to food supplements, but also to energy drinks and other foods. In this series of risk assessments of "other substances" the VKM has not evaluated any claimed beneficial effects from these substances, only possible adverse effects. The present report is a risk assessment of specified doses of beta-alanine in food supplements, and it is based on previous risk assessments and articles retrieved from literature searches. According to information from NFSA, beta-alanine is an ingredient in food supplements sold in Norway. NSFA has requested a risk assessment of beta-alanine: 1000, 1500 and 2000 mg/day from food supplements. Beta-alanine is a non-essential, non-proteogenic naturally occurring beta amino acid. Beta-alanine is a component of the naturally occurring peptides carnosine, anserine and balenine. Supplementation with beta-alanine leads to an increased production of the peptide carnosine, which is found in high concentrations in the skeletal muscle of both vertebrates and non-vertebrates. Data suggest that beta-alanine functions as a small molecule neurotransmitter and should join the ranks of the other amino acid neurotransmitters. The only observed adverse effect from beta-alanin supplementation in humans is transient (1-2 hours) paraesthesia and flushing. Paraesthesia is characterised by a stinging or prickling sensation in the skin. There is no evidence that the paraesthesia in the skin is harmful in any way. Long-term studies in humans were not found. Four small human clinical studies have been included in this risk assessment. The occurrence of paraesthesia apparently is dependent on the magnitude of the individual doses that the daily dose is split into. Single doses of beta-alanine of 10 mg/kg bw (700 mg in a 70 kg person) or more provoked transient paraesthesia. Symptom occurrence and severity increased with the dose. Repeated intakes of 5 mg beta-alanine/kg bw or less taken with >2 hours intervals did not induce paraesthesia. Haematology and plasma clinical chemistry was found normal after daily doses of 2.8 g and 3.2 g for 4 weeks in healthy adults. Apart from occasional paraesthesia, a daily dose of 6.4 g for up to seven weeks did not induce any adverse clinical effects in healthy adults of 80 kg, corresponding to a dose of 5.6 g per day in a 70-kg person. We are not aware of any data indicating that children and adolescents are more vulnerable than adults for supplementation with beta-alanine on a per kg bw basis. No relevant animal studies were identified. VKM concludes that: In adults (≥18 years), the specified doses 1000, 1500 and 2000 mg/day of beta-alanine in food supplements are unlikely to cause adverse health effects provided that beta-alanine is consumed with maximum 5 mg/kg bw per intake and a minimum of 2 hours between the intakes. In adolescents (14 to <18 years) and children (10 to <14 years) the specified doses 1000, 1500 and 2000 mg/day of beta-alanine in food supplements are unlikely to cause adverse health effects provided that beta-alanine is consumed with maximum 5 mg/kg bw per intake and a minimum of 2 hours between the intakes. Children younger than 10 years were not within the scope of the present risk assessment.
- 29 October 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 345-347
Risk Assessment of Magnesium in Food Supplements
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the risk associated with magnesium in food supplements. VKM is requested to evaluate upper tolerable intake levels for magnesium and high and low intakes in the Norwegian population. Pending establishment of common maximum limits in the EU, the NFSA is evaluating the national maximum limits for vitamins and minerals in food supplements. This risk assessment is the scientific basis for NFSA's evaluation of national limits for magnesium. Directive 2002/46/EC on food supplements was implemented in Norwegian law in 2004 in Regulation 20 May 2004 No. 755 on food supplements. Common maximum and minimum levels of vitamins and minerals in food supplements shall be set in the EU. Until common limits are established in the EU, the national limits apply. The present report is a risk assessment of magnesium in food supplements. It is based on published articles retrieved from literature searches and previous risk assessments of magnesium. Magnesium is an essential alkaline mineral and occurs as free cation Mg2+ in aqueous solution, or as the mineral part of a large variety of compounds such as chlorides, carbonates and hydroxides. Dietary sources of magnesium include green leafy vegetables, legumes, whole grain cereals, dark chocolate, nuts, fish and seafood, banana and coffee. NFSA has especially requested VKM to consider water as a source of magnesium. A few waterworks reported magnesium concentrations at 10 mg/L. Consumption of water from these waterworks may contribute up to 10% of recommended magnesium intake. However, most waterworks reported negligible magnesium concentrations. Magnesium has multiple functions in the body; it is a required cofactor for more than 300 enzyme systems in the body; for energy-dependent membrane transport, for gene regulation, and for sustained electrical potential in excitable cells. Magnesium also plays a major role in bone and mineral homeostasis. No tolerable upper intake level (UL) has been established for magnesium intake from food sources for the reason that no adverse effects have been recognised in healthy populations. Magnesium salts in food supplements may cause osmotic diarrhoea which is the most frequently reported adverse effect. However, these effects are considered relatively mild. Previous reports have arrived on UL or guidance levels (GLs) for supplemental magnesium ranging from 250 mg/day in the EU (Scientific Committee for Food (SCF, 2001)) through 350 mg/day in the USA (Institute of Medicine (IOM, 1997)) and up to 400 mg per day in the UK (Expert group on Vitamins and Minerals (EVM, 2003)). The UL from SCF (2001) is below the recommended daily dietary intakes for adults. Since the critical endpoint (gastrointestinal symptoms) is mild, rapidly reversible and no NOAEL could be identified, VKM finds it appropriate to base the UL for magnesium salts in food supplements on the LOAEL from IOM (1997). For the same reason, an uncertainty factor of 1 may be applicable for establishing a UL for magnesium salts in food supplements. VKM therefore proposes an amendment of the ULs suggested by SCF (2001) for magnesium in supplements. The IOM (1997) suggestion of a UL at 350 mg supplementary magnesium per day for adults was based on a LOAEL for mild diarrhea. VKM found no results to support an alteration of this UL. VKM therefore suggests a UL of 350 mg magnesium in food supplements per day in adults which is in accordance with the UL suggested by (IOM, 1997). This UL will also cover the recommended intakes for the adult population. VKM suggests that the ULs for children equal the recommended intakes for each age group: Age group ULs (mg/day) Children 1-3 years 85 Children 3-10 years 120-200 Children (10-<14 years) 280 Adolescents (14-<18 years) 280 Adults (≥18 years) 350 According to the habitual dietary intakes of magnesium estimated from nationwide dietary surveys in Norway, about 25% of adults have intakes of magnesium below the recommendations from food and supplements. Almost the same percentage was below the recommended intakes among 9-year-old children, while approximately 70% of 13-year-olds had an intake of magnesium below the recommendations. It should be noted that the intakes have been estimated with use of different dietary survey methods for the different age categories and a comparison of estimates across age groups can be misleading and has a high degree of uncertainty. Concentration of magnesium in water is low and about 60% of the waterworks reporting to the Norwegian Waterworks Registry had a magnesium concentration below 2 mg/L, indicating water as a negligible source of magnesium for the majority of the population.
- 29 October 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 345-347
Risk Assessment of Magnesium in Food Supplements
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the risk associated with magnesium in food supplements. VKM is requested to evaluate upper tolerable intake levels for magnesium and high and low intakes in the Norwegian population. Pending establishment of common maximum limits in the EU, the NFSA is evaluating the national maximum limits for vitamins and minerals in food supplements. This risk assessment is the scientific basis for NFSA's evaluation of national limits for magnesium. Directive 2002/46/EC on food supplements was implemented in Norwegian law in 2004 in Regulation 20 May 2004 No. 755 on food supplements. Common maximum and minimum levels of vitamins and minerals in food supplements shall be set in the EU. Until common limits are established in the EU, the national limits apply. The present report is a risk assessment of magnesium in food supplements. It is based on published articles retrieved from literature searches and previous risk assessments of magnesium. Magnesium is an essential alkaline mineral and occurs as free cation Mg2+ in aqueous solution, or as the mineral part of a large variety of compounds such as chlorides, carbonates and hydroxides. Dietary sources of magnesium include green leafy vegetables, legumes, whole grain cereals, dark chocolate, nuts, fish and seafood, banana and coffee. NFSA has especially requested VKM to consider water as a source of magnesium. A few waterworks reported magnesium concentrations at 10 mg/L. Consumption of water from these waterworks may contribute up to 10% of recommended magnesium intake. However, most waterworks reported negligible magnesium concentrations. Magnesium has multiple functions in the body; it is a required cofactor for more than 300 enzyme systems in the body; for energy-dependent membrane transport, for gene regulation, and for sustained electrical potential in excitable cells. Magnesium also plays a major role in bone and mineral homeostasis. No tolerable upper intake level (UL) has been established for magnesium intake from food sources for the reason that no adverse effects have been recognised in healthy populations. Magnesium salts in food supplements may cause osmotic diarrhoea which is the most frequently reported adverse effect. However, these effects are considered relatively mild. Previous reports have arrived on UL or guidance levels (GLs) for supplemental magnesium ranging from 250 mg/day in the EU (Scientific Committee for Food (SCF, 2001)) through 350 mg/day in the USA (Institute of Medicine (IOM, 1997)) and up to 400 mg per day in the UK (Expert group on Vitamins and Minerals (EVM, 2003)). The UL from SCF (2001) is below the recommended daily dietary intakes for adults. Since the critical endpoint (gastrointestinal symptoms) is mild, rapidly reversible and no NOAEL could be identified, VKM finds it appropriate to base the UL for magnesium salts in food supplements on the LOAEL from IOM (1997). For the same reason, an uncertainty factor of 1 may be applicable for establishing a UL for magnesium salts in food supplements. VKM therefore proposes an amendment of the ULs suggested by SCF (2001) for magnesium in supplements. The IOM (1997) suggestion of a UL at 350 mg supplementary magnesium per day for adults was based on a LOAEL for mild diarrhea. VKM found no results to support an alteration of this UL. VKM therefore suggests a UL of 350 mg magnesium in food supplements per day in adults which is in accordance with the UL suggested by (IOM, 1997). This UL will also cover the recommended intakes for the adult population. VKM suggests that the ULs for children equal the recommended intakes for each age group: Age group ULs (mg/day) Children 1-3 years 85 Children 3-10 years 120-200 Children (10-<14 years) 280 Adolescents (14-<18 years) 280 Adults (≥18 years) 350 According to the habitual dietary intakes of magnesium estimated from nationwide dietary surveys in Norway, about 25% of adults have intakes of magnesium below the recommendations from food and supplements. Almost the same percentage was below the recommended intakes among 9-year-old children, while approximately 70% of 13-year-olds had an intake of magnesium below the recommendations. It should be noted that the intakes have been estimated with use of different dietary survey methods for the different age categories and a comparison of estimates across age groups can be misleading and has a high degree of uncertainty. Concentration of magnesium in water is low and about 60% of the waterworks reporting to the Norwegian Waterworks Registry had a magnesium concentration below 2 mg/L, indicating water as a negligible source of magnesium for the majority of the population.
- 15 September 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 243-244
Assessment of Zinc Intake in Relation to Tolerable Upper Intake Levels
The Norwegian Food Safety Authority (NFSA, Mattilsynet) has requested the Norwegian Scientific Committee for Food Safety (VKM) to assess the intake of iron zinc in the Norwegian population in relation to tolerable upper intake levels (ULs). The existing maximum limit for zinc in food supplements is 25 mg/day. VKM has also conducted scenario calculations to illustrate the consequences of amending the maximum limit to 1, 2, 5, 10, 15 or 20 mg/day. Zinc is an essential trace element required for RNA, DNA and protein synthesis, cellular division, differentiation and growth (Mac Donald, 2000). Zinc is required for catalytic function in several enzymes and participates in all major biochemical pathways in the body. The function of the immune system depends on the ability of its cells to proliferate and differentiate, which is impaired in individuals with suboptimal zinc status (Barton et al. 2000). Due to its role in cell division and differentiation, adequate zinc nutrition is particularly important in children, and the requirements per kg body weight are highest in early life. The endogenous intestinal losses can vary from 7 mmol/day (0.5 mg/day) to more than 45 mmol/day (3 mg/day), depending on zinc intake (King and Turnlund, 1989). The requirements for zinc vary according to age and bioavailability. Several bioactive compounds in food such as tannins and phytic acids interact with zinc absorption and increase zinc requirements. The requirements vary twenty-fold according to life stage and diet. Zinc supplements, even at or slightly above the recommended intakes, can cause nausea and vomiting. The main concern with chronic zinc excess is, however, copper deficiency which is associated with several chronical illnesses. However, copper deficiency is uncommon due to the ubiquitous presence of copper in the diet. VKM proposes to use the ULs set by IOM (2001) as they provide values also for children and adolescents. The tolerable upper intake level set for adults is 40 mg zinc per day from food (and water) and supplements. Based on the scenario estimations, a dietary zinc intake at the 95th percentile and additionally 20 mg zinc from food supplements will lead to an intake close to the tolerable upper intake level established by IOM for adults. For adolescents and child populations the maximum amounts are 15 and 5 mg for 13- and 9-year-olds, respectively. For 2 and 4-yearolds, P95 from intake of zinc from food alone exceeds the UL.
- 15 September 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 243-244
Assessment of Zinc Intake in Relation to Tolerable Upper Intake Levels
The Norwegian Food Safety Authority (NFSA, Mattilsynet) has requested the Norwegian Scientific Committee for Food Safety (VKM) to assess the intake of iron zinc in the Norwegian population in relation to tolerable upper intake levels (ULs). The existing maximum limit for zinc in food supplements is 25 mg/day. VKM has also conducted scenario calculations to illustrate the consequences of amending the maximum limit to 1, 2, 5, 10, 15 or 20 mg/day. Zinc is an essential trace element required for RNA, DNA and protein synthesis, cellular division, differentiation and growth (Mac Donald, 2000). Zinc is required for catalytic function in several enzymes and participates in all major biochemical pathways in the body. The function of the immune system depends on the ability of its cells to proliferate and differentiate, which is impaired in individuals with suboptimal zinc status (Barton et al. 2000). Due to its role in cell division and differentiation, adequate zinc nutrition is particularly important in children, and the requirements per kg body weight are highest in early life. The endogenous intestinal losses can vary from 7 mmol/day (0.5 mg/day) to more than 45 mmol/day (3 mg/day), depending on zinc intake (King and Turnlund, 1989). The requirements for zinc vary according to age and bioavailability. Several bioactive compounds in food such as tannins and phytic acids interact with zinc absorption and increase zinc requirements. The requirements vary twenty-fold according to life stage and diet. Zinc supplements, even at or slightly above the recommended intakes, can cause nausea and vomiting. The main concern with chronic zinc excess is, however, copper deficiency which is associated with several chronical illnesses. However, copper deficiency is uncommon due to the ubiquitous presence of copper in the diet. VKM proposes to use the ULs set by IOM (2001) as they provide values also for children and adolescents. The tolerable upper intake level set for adults is 40 mg zinc per day from food (and water) and supplements. Based on the scenario estimations, a dietary zinc intake at the 95th percentile and additionally 20 mg zinc from food supplements will lead to an intake close to the tolerable upper intake level established by IOM for adults. For adolescents and child populations the maximum amounts are 15 and 5 mg for 13- and 9-year-olds, respectively. For 2 and 4-yearolds, P95 from intake of zinc from food alone exceeds the UL.
- 15 September 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 247-249
Assessment of Vitamin E Intake in Relation to Tolerable Upper Intake Levels
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the intake of vitamin E (alpha-tocopherol) in the Norwegian population in relation to tolerable upper intake levels (ULs). The existing maximum limit for vitamin E in food supplements is 30 mg/day. VKM was also requested to conduct scenario calculations to illustrate the consequences of amending the maximum limit for alpha-tocopherol to 15, 50, 100, 150, 200 and 300 mg/day. Naturally vitamin E is a fat soluble compound synthesised by plants and consists of eight different tocopherols (α-, β-, γ- and δ- tocopherols and α-, β-, γ- and δ- tocotrienols) with varying vitamin E antioxidant activity. α-Tocopherol is recognised to meet human vitamin E requirements and accounts for 90% of the activity in human tissue. Vitamin E activity in food is expressed as α-tocopherol equivalents (α-TE) and 1 α-TE is defined as 1 mg d-αtocopherol. The physiological role of vitamin E is to react with free radicals in cell membranes and other lipid milieu, thereby preventing polyunsaturated fatty acids (PUFA) from being damaged by lipid peroxidation. This antioxidant activity is important to maintain membrane integrity and takes place in all cells in the body. Vitamin E deficiency symptoms include peripheral neuropathy, ataxia, myopathy and retinopathy. Vitamin E is dependent on lipid and lipoprotein metabolism and it takes decades for body depletion. The Norwegian recommended intakes for vitamin E for adults are 10 αTE/day for men and 8 α-TE/day for women. There is no evidence of adverse effects from the consumption of vitamin E naturally occurring in foods. Animal studies have shown that α-tocopherol is not mutagenic, carcinogenic or teratogenic. However, high doses of α-tocopherol supplements can cause haemorrhage and interrupt blood coagulation. VKM propose to adopt the tolerable upper intake level set by the Scientific Committee for Food Safety (SCF) which is based on one human dose-response study. Hence, the upper level for supplemental vitamin E is suggested to 300 mg/day for adults. The upper level for children and adolescents is derived from scaling the adult upper level based on body surface area (body weight 0.75). The tolerable upper intake levels set for vitamin E concern only intake from supplements, since intake of vitamin E from the diet is considered safe. VKM has therefore not conducted or evaluated scenarios with intake from both diet and supplements. Dietary calculations have, however, been performed for intake in various percentiles (P) P5, P25, mean, P50, P75 and P95 in children (2- 4- and 9-year-olds), adolescents (13-year-olds) and in adult men and women as background information. Mean and median intakes of vitamin E are above the recommended intakes for all age groups. No age group reaches the recommended intake at P5, and 9- and 13-year-old boys and 9-year-old girls do not reach the recommended intake at P25 from diet alone. Because the tolerable upper intake level for supplemental vitamin E for adults is 300 mg/day, none of the suggested amendments of the maximum limit in food supplements (to 15, 50, 100, 150, 200 and 300 mg/day) will lead to exceedance of this upper level in adults. In 13year-olds supplements with 300 mg/day vitamin E will lead to exceedance of the upper level. In 9-year-olds supplements with 200 mg/day vitamin E will lead to exceedance of the upper level. In 4- and 2-year-olds supplements with 150 mg/day vitamin E will lead to exceedance of the upper level. Vitamin E intake from fortified products is not included in the calculations, but are however, evaluated to be very low.
- 15 September 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 247-249
Assessment of Vitamin E Intake in Relation to Tolerable Upper Intake Levels
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the intake of vitamin E (alpha-tocopherol) in the Norwegian population in relation to tolerable upper intake levels (ULs). The existing maximum limit for vitamin E in food supplements is 30 mg/day. VKM was also requested to conduct scenario calculations to illustrate the consequences of amending the maximum limit for alpha-tocopherol to 15, 50, 100, 150, 200 and 300 mg/day. Naturally vitamin E is a fat soluble compound synthesised by plants and consists of eight different tocopherols (α-, β-, γ- and δ- tocopherols and α-, β-, γ- and δ- tocotrienols) with varying vitamin E antioxidant activity. α-Tocopherol is recognised to meet human vitamin E requirements and accounts for 90% of the activity in human tissue. Vitamin E activity in food is expressed as α-tocopherol equivalents (α-TE) and 1 α-TE is defined as 1 mg d-αtocopherol. The physiological role of vitamin E is to react with free radicals in cell membranes and other lipid milieu, thereby preventing polyunsaturated fatty acids (PUFA) from being damaged by lipid peroxidation. This antioxidant activity is important to maintain membrane integrity and takes place in all cells in the body. Vitamin E deficiency symptoms include peripheral neuropathy, ataxia, myopathy and retinopathy. Vitamin E is dependent on lipid and lipoprotein metabolism and it takes decades for body depletion. The Norwegian recommended intakes for vitamin E for adults are 10 αTE/day for men and 8 α-TE/day for women. There is no evidence of adverse effects from the consumption of vitamin E naturally occurring in foods. Animal studies have shown that α-tocopherol is not mutagenic, carcinogenic or teratogenic. However, high doses of α-tocopherol supplements can cause haemorrhage and interrupt blood coagulation. VKM propose to adopt the tolerable upper intake level set by the Scientific Committee for Food Safety (SCF) which is based on one human dose-response study. Hence, the upper level for supplemental vitamin E is suggested to 300 mg/day for adults. The upper level for children and adolescents is derived from scaling the adult upper level based on body surface area (body weight 0.75). The tolerable upper intake levels set for vitamin E concern only intake from supplements, since intake of vitamin E from the diet is considered safe. VKM has therefore not conducted or evaluated scenarios with intake from both diet and supplements. Dietary calculations have, however, been performed for intake in various percentiles (P) P5, P25, mean, P50, P75 and P95 in children (2- 4- and 9-year-olds), adolescents (13-year-olds) and in adult men and women as background information. Mean and median intakes of vitamin E are above the recommended intakes for all age groups. No age group reaches the recommended intake at P5, and 9- and 13-year-old boys and 9-year-old girls do not reach the recommended intake at P25 from diet alone. Because the tolerable upper intake level for supplemental vitamin E for adults is 300 mg/day, none of the suggested amendments of the maximum limit in food supplements (to 15, 50, 100, 150, 200 and 300 mg/day) will lead to exceedance of this upper level in adults. In 13year-olds supplements with 300 mg/day vitamin E will lead to exceedance of the upper level. In 9-year-olds supplements with 200 mg/day vitamin E will lead to exceedance of the upper level. In 4- and 2-year-olds supplements with 150 mg/day vitamin E will lead to exceedance of the upper level. Vitamin E intake from fortified products is not included in the calculations, but are however, evaluated to be very low.
- 15 September 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 255-256
Assessment of Iron Intake in Relation to Tolerable Upper Intake Levels
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the intake of iron in the Norwegian population in relation to tolerable upper intake levels (ULs). The existing maximum limit for iron in food supplements is 27 mg/day. VKM has also conducted scenario calculations to illustrate the consequences of amending the maximum limit to 5, 10, 20, 30, 40 or 50 mg/day. Iron deficiency is one of the most common nutritional disorders in the world. Individuals with increased iron demand such as growing children and pregnant women, those who experience blood loss such as menstruating women are particularly at risk for the consequences or iron deficiency. Iron deficiency can lead to fatigue and anaemia. The most common adverse effects of iron supplementation are reversible gastrointestinal symptoms. Chronic iron excess can lead to iron overload which is associated with several irreversible severe health outcomes such as cancers and cardiovascular diseases. Up to 1% of the population have a genetic trait that leads to accumulation of iron and renders them more vulnerable to iron excess. An adult needs approximately 10 mg iron per day to overcome daily loss. The tolerable upper intake level (UL) for iron in adults range from 45 to 60 mg/day. However, all previous reports acknowledge the challenges in defining upper levels. The Expert Group on Vitamins and minerals (EVM), UK report provided a guidance level (GL) of 17 instead of a UL and the Nordic Nutrition Recommendations (NNR) (2012) suggested an UL of 60 mg/day, but did not suggest any clear upper levels for children. Institute of Medicine (IOM), US (2001) gives the most substantiated tolerable upper intake levels based on gastrointestinal effects, which is 40 mg/day for infants and children, regardless of age, and 45 mg/day for adolescents and adults. The Joint FAO/WHO Expert Committee on Food Additives 2003 (JECFA) also took the potential serious effects of iron overload into account and suggested a GL of 50 mg/day in adults or 0.8 mg/kg per day in children and adolescents. Because the risks and consequences from overload are significant and potentially serious, VKM suggests that the GL from JECFA (2003) is used. Using the GL from JECFA (2003), none of the suggested doses can be given to 2 or 4-yearold children, 9 year olds can add 5 mg iron from supplements, 13 year olds 20, and adults 30 mg without exceeding the guidance levels.
- 15 September 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 255-256
Assessment of Iron Intake in Relation to Tolerable Upper Intake Levels
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the intake of iron in the Norwegian population in relation to tolerable upper intake levels (ULs). The existing maximum limit for iron in food supplements is 27 mg/day. VKM has also conducted scenario calculations to illustrate the consequences of amending the maximum limit to 5, 10, 20, 30, 40 or 50 mg/day. Iron deficiency is one of the most common nutritional disorders in the world. Individuals with increased iron demand such as growing children and pregnant women, those who experience blood loss such as menstruating women are particularly at risk for the consequences or iron deficiency. Iron deficiency can lead to fatigue and anaemia. The most common adverse effects of iron supplementation are reversible gastrointestinal symptoms. Chronic iron excess can lead to iron overload which is associated with several irreversible severe health outcomes such as cancers and cardiovascular diseases. Up to 1% of the population have a genetic trait that leads to accumulation of iron and renders them more vulnerable to iron excess. An adult needs approximately 10 mg iron per day to overcome daily loss. The tolerable upper intake level (UL) for iron in adults range from 45 to 60 mg/day. However, all previous reports acknowledge the challenges in defining upper levels. The Expert Group on Vitamins and minerals (EVM), UK report provided a guidance level (GL) of 17 instead of a UL and the Nordic Nutrition Recommendations (NNR) (2012) suggested an UL of 60 mg/day, but did not suggest any clear upper levels for children. Institute of Medicine (IOM), US (2001) gives the most substantiated tolerable upper intake levels based on gastrointestinal effects, which is 40 mg/day for infants and children, regardless of age, and 45 mg/day for adolescents and adults. The Joint FAO/WHO Expert Committee on Food Additives 2003 (JECFA) also took the potential serious effects of iron overload into account and suggested a GL of 50 mg/day in adults or 0.8 mg/kg per day in children and adolescents. Because the risks and consequences from overload are significant and potentially serious, VKM suggests that the GL from JECFA (2003) is used. Using the GL from JECFA (2003), none of the suggested doses can be given to 2 or 4-yearold children, 9 year olds can add 5 mg iron from supplements, 13 year olds 20, and adults 30 mg without exceeding the guidance levels.
- 15 September 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 233-236
Assessment of Dietary Intake of Vitamin C and Calcium in the Norwegian Population
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), evaluated the intake of vitamin C and calcium in the Norwegian population. VKM has also conducted scenario estimations to illustrate the consequences of amending maximum limits for vitamin C (to 100, 300, 500, 600, 800 or 1000 mg/day) and calcium (to 800, 1200 or 2000 mg/day) in food supplements. Vitamin C: Vitamin C refers to both ascorbic acid and dehydroascorbic acid. Scurvy is the manifestation of vitamin C deficiency which is preventable by a daily intake of 5-10 mg/day. Fruits, berries and vegetables are important food sources of vitamin C and especially citrus fruit are important contributors. The Norwegian recommendation for dietary intake of vitamin C is 75 mg/day for adults (Helsedirektoratet, 2014). Vitamin C is absorbed from the intestine by an active process that is dose dependent. The bioavailability is at least 80% for doses up to 100 mg, 70% for doses of 200-500 mg and less than 50% for doses exceeding 1000 mg. Intestinal discomfort and diarrhea have been reported by persons using large doses (>1000 mg/day) of vitamin C supplementation. In 2000 the Institute of Medicine (IOM) in the USA proposed a tolerable upper intake level (UL) for vitamin C intake from food and supplements of 2000 mg/day for adults. ULs for children and adolescents were extrapolated based on body weight; 400 mg for children 1-3 years, 650 mg/day for children 4-8 years, 1200 mg/day for 9-13 years old adolescents, 1800 mg/day for 14-18 years old (IOM, 2000). In the assessment of vitamin C, VKM uses the Norwegian recommendations for intakes (Helsedirektoratet, 2014), and the acceptable dose for supplemental vitamin C from EFSA (2004) for adults and the tolerable upper intake levels established by the IOM (2000) for children and adolescents. Daily intakes of vitamin C from diet and supplements are estimated from nationwide dietary surveys performed in selected age groups: Adults 18-70 years, adolescents aged 13 years, and children aged 2, 4, and 9 years. Not all age-groups in the Norwegian population reach the recommended intake of vitamin C. At the 5th percentile, only 13-year-olds have an intake of vitamin C from food alone above the recommendations. At the 25th percentile, all age groups except adults have a vitamin C intake from food alone at or above the recommendations. At the 40th percentile, adults reach the recommended intake of vitamin C. The whole population would reach the recommended dietary intake with supplementation of 100 mg vitamin C per day. All the alternative maximum limits for vitamin C in food supplements listed in the terms of reference from NFSA (100, 300, 500, 600, 800 or 1000 mg/day) will be within the acceptable dose for supplemental vitamin C suggested by EFSA (2004) for adults. None of the alternative maximum limits for vitamin C in food supplements listed in the terms of reference (100, 300, 500, 600, 800 or 1000 mg/day) leads to exceedance of the tolerable upper intake levels established by IOM in adults, 13- year-olds or 9-year-olds, even with intakes from food at the 95th percentile. However, the tolerable upper intake level proposed by the IOM will be exceeded for 4-year-old children at supplemental doses above 500 mg vitamin C per day, and for 2-year-old children at doses higher than 100 mg/day. Calcium: Calcium is the most abundant mineral in the body and constitutes approximately 1200 g and 1400 g in adult women and men, respectively. More than 99% of the calcium in the body is bound to hydroxyapatite in bone and tooth enamel. Calcium is crucial for many bodily functions such as cell signalling, coagulation, muscular contraction, and neural transmission as well as skeletal integrity. Milk and dairy products are the main dietary sources of calcium, but foods such as fish, pulses, nuts, seeds (especially millet) and green vegetables may contribute to the total intake. The Norwegian recommendation for dietary intake of calcium is 800 mg/day for adults. The bioavailability of calcium is dependent on the amount of calcium ingested as well as the individual’s vitamin D status and physiological needs, like e.g. growth and pregnancy. Adverse effects of excessive calcium intake include symptoms of hypercalcaemia such as e.g. anorexia, weight loss, polyuria, heart arrhythmias, fatigue and soft tissue calcification (Jones, 2008 in IOM, 2011), deterioration of kidney function, kidney stone formation, the milk-alkali syndrome and vascular calcification. In 2012 the European Food Safety Authority (EFSA) established a tolerable upper intake level (UL) for calcium at 2500 mg/day from food and supplements for adults. No UL was set for children and adolescents. In 2011, IOM established a UL for 1-8 years old children to 2500 mg/day and 3000 mg/day for 9-18 years old children and adolescents (IOM, 2011). VKM however suggests that the UL established for adults by EFSA (2012) is used for the purpose of this VKM opinion also for children and adolescents, as the ULs from IOM for children and adolescents are considered to be high. In the assessment of calcium, VKM uses the Norwegian recommendations for intakes (Helsedirektoratet, 2014) and the tolerable upper intake levels established by the European Food Safety Authority for adults (includes both foods and supplements) (EFSA, 2012). Daily intakes of calcium from diet and supplements are estimated from nationwide dietary surveys performed in selected age groups: Adults 18-70 years, adolescents aged 13 years, and children aged 2, 4, and 9 years. Not all age groups in the Norwegian population reach the recommended intake of calcium. At the 5th percentile, no age groups fulfil the recommended daily intakes of calcium from food alone, and in the 50th percentile the 13-year-olds did not reach the recommended intake for calcium from...
- 15 September 2018
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 8 (4) , 233-236
Assessment of Dietary Intake of Vitamin C and Calcium in the Norwegian Population
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), evaluated the intake of vitamin C and calcium in the Norwegian population. VKM has also conducted scenario estimations to illustrate the consequences of amending maximum limits for vitamin C (to 100, 300, 500, 600, 800 or 1000 mg/day) and calcium (to 800, 1200 or 2000 mg/day) in food supplements. Vitamin C: Vitamin C refers to both ascorbic acid and dehydroascorbic acid. Scurvy is the manifestation of vitamin C deficiency which is preventable by a daily intake of 5-10 mg/day. Fruits, berries and vegetables are important food sources of vitamin C and especially citrus fruit are important contributors. The Norwegian recommendation for dietary intake of vitamin C is 75 mg/day for adults (Helsedirektoratet, 2014). Vitamin C is absorbed from the intestine by an active process that is dose dependent. The bioavailability is at least 80% for doses up to 100 mg, 70% for doses of 200-500 mg and less than 50% for doses exceeding 1000 mg. Intestinal discomfort and diarrhea have been reported by persons using large doses (>1000 mg/day) of vitamin C supplementation. In 2000 the Institute of Medicine (IOM) in the USA proposed a tolerable upper intake level (UL) for vitamin C intake from food and supplements of 2000 mg/day for adults. ULs for children and adolescents were extrapolated based on body weight; 400 mg for children 1-3 years, 650 mg/day for children 4-8 years, 1200 mg/day for 9-13 years old adolescents, 1800 mg/day for 14-18 years old (IOM, 2000). In the assessment of vitamin C, VKM uses the Norwegian recommendations for intakes (Helsedirektoratet, 2014), and the acceptable dose for supplemental vitamin C from EFSA (2004) for adults and the tolerable upper intake levels established by the IOM (2000) for children and adolescents. Daily intakes of vitamin C from diet and supplements are estimated from nationwide dietary surveys performed in selected age groups: Adults 18-70 years, adolescents aged 13 years, and children aged 2, 4, and 9 years. Not all age-groups in the Norwegian population reach the recommended intake of vitamin C. At the 5th percentile, only 13-year-olds have an intake of vitamin C from food alone above the recommendations. At the 25th percentile, all age groups except adults have a vitamin C intake from food alone at or above the recommendations. At the 40th percentile, adults reach the recommended intake of vitamin C. The whole population would reach the recommended dietary intake with supplementation of 100 mg vitamin C per day. All the alternative maximum limits for vitamin C in food supplements listed in the terms of reference from NFSA (100, 300, 500, 600, 800 or 1000 mg/day) will be within the acceptable dose for supplemental vitamin C suggested by EFSA (2004) for adults. None of the alternative maximum limits for vitamin C in food supplements listed in the terms of reference (100, 300, 500, 600, 800 or 1000 mg/day) leads to exceedance of the tolerable upper intake levels established by IOM in adults, 13- year-olds or 9-year-olds, even with intakes from food at the 95th percentile. However, the tolerable upper intake level proposed by the IOM will be exceeded for 4-year-old children at supplemental doses above 500 mg vitamin C per day, and for 2-year-old children at doses higher than 100 mg/day. Calcium: Calcium is the most abundant mineral in the body and constitutes approximately 1200 g and 1400 g in adult women and men, respectively. More than 99% of the calcium in the body is bound to hydroxyapatite in bone and tooth enamel. Calcium is crucial for many bodily functions such as cell signalling, coagulation, muscular contraction, and neural transmission as well as skeletal integrity. Milk and dairy products are the main dietary sources of calcium, but foods such as fish, pulses, nuts, seeds (especially millet) and green vegetables may contribute to the total intake. The Norwegian recommendation for dietary intake of calcium is 800 mg/day for adults. The bioavailability of calcium is dependent on the amount of calcium ingested as well as the individual’s vitamin D status and physiological needs, like e.g. growth and pregnancy. Adverse effects of excessive calcium intake include symptoms of hypercalcaemia such as e.g. anorexia, weight loss, polyuria, heart arrhythmias, fatigue and soft tissue calcification (Jones, 2008 in IOM, 2011), deterioration of kidney function, kidney stone formation, the milk-alkali syndrome and vascular calcification. In 2012 the European Food Safety Authority (EFSA) established a tolerable upper intake level (UL) for calcium at 2500 mg/day from food and supplements for adults. No UL was set for children and adolescents. In 2011, IOM established a UL for 1-8 years old children to 2500 mg/day and 3000 mg/day for 9-18 years old children and adolescents (IOM, 2011). VKM however suggests that the UL established for adults by EFSA (2012) is used for the purpose of this VKM opinion also for children and adolescents, as the ULs from IOM for children and adolescents are considered to be high. In the assessment of calcium, VKM uses the Norwegian recommendations for intakes (Helsedirektoratet, 2014) and the tolerable upper intake levels established by the European Food Safety Authority for adults (includes both foods and supplements) (EFSA, 2012). Daily intakes of calcium from diet and supplements are estimated from nationwide dietary surveys performed in selected age groups: Adults 18-70 years, adolescents aged 13 years, and children aged 2, 4, and 9 years. Not all age groups in the Norwegian population reach the recommended intake of calcium. At the 5th percentile, no age groups fulfil the recommended daily intakes of calcium from food alone, and in the 50th percentile the 13-year-olds did not reach the recommended intake for calcium from...
- 1 September 2016
- Published by Elsevier in Toxicology Letters
- Vol. 258, S25
Exposure to endocrine disruptors accelerates diabetes type 1 development in NOD mice via impaired macrophage function
- 1 September 2016
- Published by Elsevier in Toxicology Letters
- Vol. 258, S25
Exposure to endocrine disruptors accelerates diabetes type 1 development in NOD mice via impaired macrophage function
- Open Access
- 10 January 2016
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 6 (2) , 79-82
Risk Assessment of Beta-carotene in Food Supplements
Beta-carotene is a provitamin, i.e. a precursor of vitamin A (retinol), which is classified as an essential nutrient for humans. Beta-carotene is one of many carotenoids found in plants, fungi and bacteria. Carotenoids are therefore predominantly obtained through foods of plant origin or food supplements. Carrots contribute approximately half of the total beta-carotene intake in the Norwegian diet, followed by mixed frozen vegetables, tomatoes, fruits and berries. VKM emphasises that this opinion on upper level (UL) for beta-carotene addresses beta-carotene in food supplements only. Beta-carotene from regular foods such as vegetables and fruits is not considered to be a health concern. In 2002, the Scientific Committee on Food (SCF) established a tolerable upper intake level (UL) for vitamin A (SCF, 2002). However, the SCF opinion covers only retinol compounds (various forms of vitamin A). The bioconversion of carotenoids to vitamin A in the body is well regulated and therefore only intake of vitamin A has been considered relevant for vitamin A toxicity (Blomhoff et al., 2003; EFSA, 2008). The Norwegian Food Safety Authority is considering whether beta-carotene should be regulated separately from retinol compounds. Beta-carotene seems to have a carcinogenic effect in smokers. A number of studies have been published where possible mechanisms of this negative health effect are discussed. The suggested mechanisms are either related to effects on cytochrome P450-related activities, altered retinoid signalling or to a pro-oxidant activity of beta-carotene. No UL has been established for beta-carotene. Several risk-assessment bodies have, however, previously attempted to establish safe levels or temporary guidelines, summarised in the following table: Seven randomised controlled trials (RCTs) have been included in this VKM opinion, conducted either in Europe or the USA, with almost 47 100 participants in the beta-carotene groups. In six of these RCTs there were no observed increased risk of cancer, but the large Finnish ATBC study found an increased risk of lung cancer in the beta-carotene group. Two prospective studies were included, one Danish and one from the USA, with 125 000 participants all together. The Danish study found that risk of lung cancer increased in smokers with increasing doses of beta-carotene supplements. In addition, eleven meta-analyses were included; one with age-related macular degeneration as endpoint, one with a mixture of cardiovascular disease (CVD) and cancer as endpoints, four on cancer as only endpoint, one on a mixture of CVD and all-cause mortality as endpoints and four on all-cause mortality alone. One of the meta-analyses on all-cause mortality was later excluded. There were no significant findings in the meta-analysis on macula degeneration. One of the two meta-analyses on CVD found a small increased risk in the beta-carotene arm (Vivekananthan et al., 2003). The combined CVD and cancer meta-analysis did not have sufficient statistical power to get significant results, but found a probable increase in lung cancer incidence in high-risk subgroups (smokers and asbestos workers (Fortmann et al., 2013). In the five meta-analyses studying cancer, there were no effect on other cancer forms than lung cancer. The four meta-analyses on all-cause mortality used information from the same RCTs as included in this VKM-opinion. They extracted information on numbers of death in each study and used these numbers to analyse risk of death in the beta-carotene versus placebo groups. Alarmingly, they all found an increased risk of all-cause mortality. These meta-analyses have been discussed thoroughly. To complete the risk characterisation of beta-carotene, VKM has followed the steps 1 – 4 as suggested by SCF in their Guidelines for the development of tolerable upper intake levels for vitamins and minerals (SCF, 2000a). Step 1 and 2. Hazard identification and characterisation Up until two decades ago, beta-carotene was thought to be harmless even in large doses. In the wake of the Finnish ATBC study which found an increased risk of lung cancer and death in male smokers, animal studies have indicated three possible mechanisms for such a detrimental effect. Although conclusive mechanistic explanations for the negative effects have not yet been agreed upon, there is a scientific rationale for the argument that population groups with vulnerable lungs may also have increased risk from beta-carotene supplements. The dose used in the Finnish ATBC study was 20 mg beta-carotene/day. The effect was only observed during the intervention period; in follow-up studies conducted after the active period was finished, the risk declined and was no longer significant. 20 mg beta-carotene may thus be considered as a LOAEL. The Danish prospective study found a dose-dependent increase in lung cancer risk with increased intake of supplemental beta-carotene. Unfortunately, the paper does not allow for setting a NOAEL or LOAEL based on the published data. In the four meta-analyses on all-cause mortality, all found a 6-7% increased risk of death. One of the meta-analyses also found an increased risk of CVD in smokers. However, all results were driven, statistically, by the ATBC study. Studies with a more mixed population (both men and women) and with a more typical prevalence of smokers (10–20%), found no such increased risk. Step 2, continued: Derive at a UL, taking into account the scientific uncertainties in the data. ULs may be derived for various life-stage groups within the population VKM found it extraordinary challenging to decide which uncertainty factor to use for beta-carotene. The present SCF guidelines for establishment of tolerable upper intake levels do not give clear guidance/advice in deciding the numeric level of the uncertainty factor. This seems to leave the decision to scientific judgement. If the NOAEL is based on human data, an...
- 10 January 2016
- Published by Sciencedomain International in European Journal of Nutrition & Food Safety
- Vol. 6 (2) , 79-82
Open AccessRisk Assessment of Beta-carotene in Food Supplements
Beta-carotene is a provitamin, i.e. a precursor of vitamin A (retinol), which is classified as an essential nutrient for humans. Beta-carotene is one of many carotenoids found in plants, fungi and bacteria. Carotenoids are therefore predominantly obtained through foods of plant origin or food supplements. Carrots contribute approximately half of the total beta-carotene intake in the Norwegian diet, followed by mixed frozen vegetables, tomatoes, fruits and berries. VKM emphasises that this opinion on upper level (UL) for beta-carotene addresses beta-carotene in food supplements only. Beta-carotene from regular foods such as vegetables and fruits is not considered to be a health concern. In 2002, the Scientific Committee on Food (SCF) established a tolerable upper intake level (UL) for vitamin A (SCF, 2002). However, the SCF opinion covers only retinol compounds (various forms of vitamin A). The bioconversion of carotenoids to vitamin A in the body is well regulated and therefore only intake of vitamin A has been considered relevant for vitamin A toxicity (Blomhoff et al., 2003; EFSA, 2008). The Norwegian Food Safety Authority is considering whether beta-carotene should be regulated separately from retinol compounds. Beta-carotene seems to have a carcinogenic effect in smokers. A number of studies have been published where possible mechanisms of this negative health effect are discussed. The suggested mechanisms are either related to effects on cytochrome P450-related activities, altered retinoid signalling or to a pro-oxidant activity of beta-carotene. No UL has been established for beta-carotene. Several risk-assessment bodies have, however, previously attempted to establish safe levels or temporary guidelines, summarised in the following table: Seven randomised controlled trials (RCTs) have been included in this VKM opinion, conducted either in Europe or the USA, with almost 47 100 participants in the beta-carotene groups. In six of these RCTs there were no observed increased risk of cancer, but the large Finnish ATBC study found an increased risk of lung cancer in the beta-carotene group. Two prospective studies were included, one Danish and one from the USA, with 125 000 participants all together. The Danish study found that risk of lung cancer increased in smokers with increasing doses of beta-carotene supplements. In addition, eleven meta-analyses were included; one with age-related macular degeneration as endpoint, one with a mixture of cardiovascular disease (CVD) and cancer as endpoints, four on cancer as only endpoint, one on a mixture of CVD and all-cause mortality as endpoints and four on all-cause mortality alone. One of the meta-analyses on all-cause mortality was later excluded. There were no significant findings in the meta-analysis on macula degeneration. One of the two meta-analyses on CVD found a small increased risk in the beta-carotene arm (Vivekananthan et al., 2003). The combined CVD and cancer meta-analysis did not have sufficient statistical power to get significant results, but found a probable increase in lung cancer incidence in high-risk subgroups (smokers and asbestos workers (Fortmann et al., 2013). In the five meta-analyses studying cancer, there were no effect on other cancer forms than lung cancer. The four meta-analyses on all-cause mortality used information from the same RCTs as included in this VKM-opinion. They extracted information on numbers of death in each study and used these numbers to analyse risk of death in the beta-carotene versus placebo groups. Alarmingly, they all found an increased risk of all-cause mortality. These meta-analyses have been discussed thoroughly. To complete the risk characterisation of beta-carotene, VKM has followed the steps 1 – 4 as suggested by SCF in their Guidelines for the development of tolerable upper intake levels for vitamins and minerals (SCF, 2000a). Step 1 and 2. Hazard identification and characterisation Up until two decades ago, beta-carotene was thought to be harmless even in large doses. In the wake of the Finnish ATBC study which found an increased risk of lung cancer and death in male smokers, animal studies have indicated three possible mechanisms for such a detrimental effect. Although conclusive mechanistic explanations for the negative effects have not yet been agreed upon, there is a scientific rationale for the argument that population groups with vulnerable lungs may also have increased risk from beta-carotene supplements. The dose used in the Finnish ATBC study was 20 mg beta-carotene/day. The effect was only observed during the intervention period; in follow-up studies conducted after the active period was finished, the risk declined and was no longer significant. 20 mg beta-carotene may thus be considered as a LOAEL. The Danish prospective study found a dose-dependent increase in lung cancer risk with increased intake of supplemental beta-carotene. Unfortunately, the paper does not allow for setting a NOAEL or LOAEL based on the published data. In the four meta-analyses on all-cause mortality, all found a 6-7% increased risk of death. One of the meta-analyses also found an increased risk of CVD in smokers. However, all results were driven, statistically, by the ATBC study. Studies with a more mixed population (both men and women) and with a more typical prevalence of smokers (10–20%), found no such increased risk. Step 2, continued: Derive at a UL, taking into account the scientific uncertainties in the data. ULs may be derived for various life-stage groups within the population VKM found it extraordinary challenging to decide which uncertainty factor to use for beta-carotene. The present SCF guidelines for establishment of tolerable upper intake levels do not give clear guidance/advice in deciding the numeric level of the uncertainty factor. This seems to leave the decision to scientific judgement. If the NOAEL is based on human data, an...
- 24 February 2015
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 81 (3) , 192-200
Cry1Ab Protein from Bacillus thuringiensis and MON810 cry1Ab -transgenic Maize Exerts No Adjuvant Effect After Airway Exposure
The genetically modified (GM) maize event MON810 has been inserted with a processed version of the transgene, cry1Ab, derived from the soil bacterium Bacillus thuringiensis (Bt) to express proteins with insecticidal properties. Such proteins may introduce new allergens and also act as adjuvants that promote allergic responses. While focus has been on safe consumption and hence the oral exposure to GM food and feed, little is known regarding inhalation of pollen and desiccated airborne plant material from GM crops. The aim of the present study was to investigate whether plant material from the Cry1Ab‐expressing maize variety MON810, or trypsin activated Cry1Ab (trypCry1Ab) protein produced in recombinant bacteria, may act as adjuvants against the allergen ovalbumin (OVA) in a mouse model of airway allergy. A clear proallergic adjuvant effect of the mucosal adjuvant Cholera toxin (CT) was demonstrated, determined as increased specific IgE, eosinophils and Th2 cytokines in MLN cell supernates, while no elevation in OVA‐specific antibodies or cytokine release from MLN cells after stimulation with OVA were observed in mice receiving Cry1Ab‐containing plant materials or the trypCry1Ab protein. Our data suggest that Cry1Ab proteins had no detectable systemic adjuvant effect in mice after airway exposure. Further experiments with purified plant proteins, as well as long term exposures needs be conducted to further evaluate exposures experienced in real life situations.
- 24 February 2015
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 81 (3) , 192-200
Cry1Ab Protein from Bacillus thuringiensis and MON810 cry1Ab -transgenic Maize Exerts No Adjuvant Effect After Airway Exposure
The genetically modified (GM) maize event MON810 has been inserted with a processed version of the transgene, cry1Ab, derived from the soil bacterium Bacillus thuringiensis (Bt) to express proteins with insecticidal properties. Such proteins may introduce new allergens and also act as adjuvants that promote allergic responses. While focus has been on safe consumption and hence the oral exposure to GM food and feed, little is known regarding inhalation of pollen and desiccated airborne plant material from GM crops. The aim of the present study was to investigate whether plant material from the Cry1Ab‐expressing maize variety MON810, or trypsin activated Cry1Ab (trypCry1Ab) protein produced in recombinant bacteria, may act as adjuvants against the allergen ovalbumin (OVA) in a mouse model of airway allergy. A clear proallergic adjuvant effect of the mucosal adjuvant Cholera toxin (CT) was demonstrated, determined as increased specific IgE, eosinophils and Th2 cytokines in MLN cell supernates, while no elevation in OVA‐specific antibodies or cytokine release from MLN cells after stimulation with OVA were observed in mice receiving Cry1Ab‐containing plant materials or the trypCry1Ab protein. Our data suggest that Cry1Ab proteins had no detectable systemic adjuvant effect in mice after airway exposure. Further experiments with purified plant proteins, as well as long term exposures needs be conducted to further evaluate exposures experienced in real life situations.